Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer

BACKGROUND: The single-arm phase II APT trial established trastuzumab and paclitaxel (TH) as the standard adjuvant regimen for small human epidermal growth factor receptor 2 (HER2+) tumors. However, paclitaxel causes alopecia and has high rates of neuropathy and hypersensitivity reactions. In patien...

Descripción completa

Detalles Bibliográficos
Autores principales: McLaughlin, Shannon, Nakajima, Erika, Bar, Yael, Hutchinson, Jennifer A., Shin, Jennifer, Moy, Beverly, Isakoff, Steven J., Bardia, Aditya, Kuter, Irene, Spring, Laura M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837262/
https://www.ncbi.nlm.nih.gov/pubmed/36643653
http://dx.doi.org/10.1177/17588359221146133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837262/
https://www.ncbi.nlm.nih.gov/pubmed/36643653
http://dx.doi.org/10.1177/17588359221146133

Ejemplares similares